Upstream / Downstream
Explore pathways related to this product.
Important Ordering DetailsCustom Ordering Details: Product is assembled upon order. Please allow up to three business days for your product to be processed.
the purchase of 3 or more products
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
SignalSilence® LC3A siRNA II #6215
This product is discontinued
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® LC3A siRNA I #6214 (+) or SignalSilence® LC3A siRNA II (+), using LC3B (G40) Antibody #4108 and β-Actin (13E5) Rabbit mAb #4970. The LC3B (G40) antibody confirms silencing of LC3A expression, while the β-Actin (13E5) Rabbit mAb is used to control for loading and specificity of LC3A siRNA. Please note #4108 recognizes LC3A and LC3C.Learn more about how we get our images
Gallery: SignalSilence® LC3A siRNA II #6215
CST recommends transfection with 100 nM LC3A siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.Storage: SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
SignalSilence® LC3A siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit LC3A expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. LC3A siRNA II specifically inhibits LC3A expression and is not expected to inhibit expression of related LC3B or LC3C isoforms. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Autophagy is a catabolic process for the autophagosomic-lysosomal degradation of bulk cytoplasmic contents (1,2). Autophagy is generally activated by conditions of nutrient deprivation, but it has also been associated with a number of physiological processes including development, differentiation, neurodegenerative diseases, infection, and cancer (3). Autophagy marker Light Chain 3 (LC3) was originally identified as a subunit of microtubule-associated proteins 1A and 1B (termed MAP1LC3) (4) and subsequently found to contain similarity to the yeast protein Apg8/Aut7/Cvt5 critical for autophagy (5). Three human LC3 isoforms (LC3A, LC3B, and LC3C) undergo post-translational modifications during autophagy (6-9). Cleavage of LC3 at the carboxy terminus immediately following synthesis yields the cytosolic LC3-I form. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles (6-10). The presence of LC3 in autophagosomes and the conversion of LC3 to the lower migrating form, LC3-II, have been used as indicators of autophagy (11).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. SignalSilence is a registered trademark of Cell Signaling Technology, Inc.